FLOW CYTOMETRY, CD 7

The Flow Cytometry CD7 Test is a specialized immunophenotyping assay used to detect and measure the expression of CD7, a cell surface glycoprotein that is one of the earliest markers expressed during T-lymphocyte development. CD7 is normally present on most mature T cells, immature T-cell precursors, and a subset of Natural Killer (NK) cells, making it an important marker in hematology and immunology.

Flow cytometry technology allows rapid analysis of thousands of cells individually, helping identify CD7-positive cell populations and evaluate their immunophenotypic characteristics. CD7 is routinely included in comprehensive flow cytometry panels used to diagnose and classify T-cell leukemias, T-cell lymphomas, NK-cell disorders, and other hematological malignancies.

Abnormal CD7 expression, including loss or aberrant expression, can provide important diagnostic information in leukemia and lymphoma evaluation. The test helps determine cell lineage, assess disease characteristics, and support treatment planning.

Benefits of the Test

• Identifies T-cell and NK-cell populations
• Assists in leukemia and lymphoma diagnosis
• Supports classification of T-cell malignancies
• Helps evaluate lymphoproliferative disorders
• Assists disease monitoring and follow-up
• Provides valuable immunophenotypic information

Why Doctors Recommend This Test

Doctors may recommend Flow Cytometry CD7 testing for:

• Suspected T-cell Acute Lymphoblastic Leukemia (T-ALL)
• T-cell lymphoma evaluation
• NK-cell neoplasm assessment
• Lymphoproliferative disorder investigation
• Abnormal lymphocyte counts
• Bone marrow disorder evaluation
• Leukemia immunophenotyping
• Monitoring hematological malignancies

The test helps identify abnormal T-cell populations and contributes to accurate disease classification.

Preparation Before Test

The test may require:

• Peripheral blood sample
• Bone marrow aspirate
• Lymph node tissue
• Body fluid specimen
• Other clinically relevant samples

Preparation generally includes:

• No fasting is required
• Inform your physician about current medications and treatments
• Follow laboratory collection instructions

The specimen is analyzed using advanced multiparameter flow cytometry systems.

Normal Reporting Time

Results are generally available within 1 to 3 working days, depending on laboratory workflow and panel complexity.

Who Should Take This Test?

• Patients with suspected leukemia
• Individuals with suspected lymphoma
• Patients with abnormal lymphocyte counts
• Individuals undergoing bone marrow evaluation
• Patients with T-cell or NK-cell disorders
• Individuals referred by hematologists or oncologists

Flow Cytometry CD7 testing is an important component of modern hematological diagnostics and T-cell immunophenotyping.

Clinical Significance

CD7 expression may be observed in:

• Normal T Lymphocytes
• T-cell Acute Lymphoblastic Leukemia (T-ALL)
• T-cell Lymphomas
• Peripheral T-cell Lymphoma
• NK-cell Neoplasms
• T-cell Lymphoproliferative Disorders
• Certain Acute Myeloid Leukemias with Aberrant T-cell Marker Expression

Loss, decreased expression, or abnormal expression of CD7 may help identify malignant cell populations and contribute to disease classification.

Important Note

CD7 is typically interpreted together with other markers such as CD2, CD3, CD4, CD5, CD8, CD16, CD56, CD34, TdT, and CD45. Comprehensive interpretation by a hematopathologist is essential for accurate diagnosis and clinical management.